Sunday, June 21, 2026
🇺🇸 FDA

Patent directory · USPTO A61K / A61P

Browse patents

Browse 30,257 pharma-relevant patents (US A61K/A61P) linked to tracked companies, drugs, and pipeline programs.

Patents indexed 30,257
Companies 1,771
Drugs linked 4,798

Quick answer

NovaPharmaNews indexes 30,257 US pharmaceutical patents from USPTO PatentsView (CPC A61K/A61P), cross-linked to company assignees, drug INN profiles, and pipeline programs. Search by patent number, applicant, title, or CPC code — or use facet hubs for expiring patents, assignees, and therapeutic areas.

Patent results

Page 504 of 1,261

  1. US 10265337

    Use of A3 adenosine receptor agonist in osteoarthritis treatment

    CAN-FITE BIOPHARMA LTD. · Granted Apr 23, 2019 · Expires Apr 18, 2039

    granted

  2. US 10266825

    Compositions comprising alternating 2′-modified nucleosides for use in gene modulation

    Ionis Pharmaceuticals, Inc. · Granted Apr 23, 2019 · Expires Apr 18, 2039

    granted

  3. US 10266588

    Method of treating osteoarthritis with an antibody to NGF

    REGENERON PHARMACEUTICALS, INC. · Granted Apr 23, 2019 · Expires Apr 18, 2039

    granted

  4. US 10266582

    GPR156 variants and uses thereof

    REGENERON PHARMACEUTICALS, INC. · Granted Apr 23, 2019 · Expires Apr 18, 2039

    granted

  5. US 10266579

    Synthetic somatostatin receptor ligands

    TEL HASHOMER MEDICAL RESEARCH INFRASTRUCTURE AND SERVICES LTD. · Granted Apr 23, 2019 · Expires Apr 18, 2039

    granted

  6. US 10266560

    Bile acid analogs as FXR/TGR5 agonists and methods of use thereof

    Enanta Pharmaceuticals, Inc. · Granted Apr 23, 2019 · Expires Apr 18, 2039

    granted

  7. US 10266565

    Peptide mimetic ligands of polo-like kinase 1 polo box domain and methods of use

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Apr 23, 2019 · Expires Apr 18, 2039

    granted

  8. US 10266542

    EZH2 inhibitors

    Mirati Therapeutics, Inc. · Granted Apr 23, 2019 · Expires Apr 18, 2039

    granted

  9. US 10266539

    Polymorph of Syk inhibitors

    GILEAD CONNECTICUT, INC. · Granted Apr 23, 2019 · Expires Apr 18, 2039

    granted

  10. US 10266529

    Salts, co-crystals, and polymorphs of an anxiolytic compound

    IRONWOOD PHARMACEUTICALS, INC. · Granted Apr 23, 2019 · Expires Apr 18, 2039

    granted

  11. US 10266521

    Substituted heteroaryl compounds and methods of use

    SUNSHINE LAKE PHARMA CO., LTD. · Granted Apr 23, 2019 · Expires Apr 18, 2039

    granted

  12. US 10266488

    4-((2-hydroxy-3-methoxybenzyl)amino)benzenesulfonamide derivatives as potent and selective inhibitors of 12-lipoxygenase

    THE UNITED STATES OF AMERICA, DEPARTMENT OF HEALTH AND HUMAN SERVICES · Granted Apr 23, 2019 · Expires Apr 18, 2039

    granted

  13. US 10266484

    Biodegradable lipids for the delivery of active agents

    Alnylam Pharmaceuticals, Inc. · Granted Apr 23, 2019 · Expires Apr 18, 2039

    granted

  14. US 10265411

    N-optionally substituted aryl-2-oligomer-3-alkoxypropionamides

    Nektar Therapeutics · Granted Apr 23, 2019 · Expires Apr 18, 2039

    granted

  15. US 10265439

    Injectable cell-laden biohybrid hydrogels for cardiac regeneration and related applications

    ARIZONA BOARD OF REGENTS FOR AND ON BEHALF OF ARIZONA STATE UNIVERSITY · Granted Apr 23, 2019 · Expires Apr 18, 2039

    granted

  16. US 10265412

    Enzyme replacement therapy for treating lysosomal storage diseases

    The Medical Research, Infrastructure and Health Services Fund of the Tel-Aviv Medical Center · Granted Apr 23, 2019 · Expires Apr 18, 2039

    granted

  17. US 10265405

    Polymers for delivery of factor VIII and/or factor IX

    The Board of Regents of the University of Texas System · Granted Apr 23, 2019 · Expires Apr 18, 2039

    granted

  18. US 10265396

    Magnetic extracellular matrix

    GREINER BIO-ONE NORTH AMERICA, INC. · Granted Apr 23, 2019 · Expires Apr 18, 2039

    granted

  19. US 10265399

    Pharmaceutical compositions comprising meloxicam

    AXSOME THERAPEUTICS, INC. · Granted Apr 23, 2019 · Expires Apr 18, 2039

    granted

  20. US 10265319

    Formulations of viloxazine

    Supernus Pharmaceuticals, Inc. · Granted Apr 23, 2019 · Expires Apr 18, 2039

    granted

  21. US 10265394

    Compositions and methods for self-adjuvanting vaccines against microbes and tumors

    The Regents of the University of California · Granted Apr 23, 2019 · Expires Apr 18, 2039

    granted

  22. US 10258701

    Labeled evans blue dye derivative for in vivo serum albumin labeling

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Apr 16, 2019 · Expires Apr 11, 2039

    granted

  23. US 10261083

    Compositions and methods for detecting protease activity in biological systems

    CytomX Therapeutics, Inc. · Granted Apr 16, 2019 · Expires Apr 11, 2039

    granted

  24. US 10260069

    Selective antisense compounds and uses thereof

    Ionis Pharmaceuticals, Inc. · Granted Apr 16, 2019 · Expires Apr 11, 2039

    granted

Frequently asked questions

What patents are included in this directory?

We index 30,257 published US pharma-relevant patents filtered to CPC classes A61K and A61P, with assignee links to our company directory where a match exists.

How do I search for a patent?

Use the search box to match patent number, title, applicant name, or CPC classification (e.g. A61K). For cross-entity queries spanning news and drugs, use the global search.

How is this different from the patent intelligence dashboard?

The dashboard at /patents highlights expirations, recent grants, and assignee rankings. Browse is the full paginated directory with search — best for looking up a specific filing or applicant portfolio slice.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.